- |||||||||| Bevyxxa (betrixaban) / AstraZeneca, Ichorcumab (JNJ-64179375) / J&J, tecarfarin (ATI-5923) / Espero BioPharma
EMERGING ANTICOAGULANTS FOR THE THROMBOPROPHYLAXIS OF ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE. (Green Room (Sunset Center)) - Dec 20, 2021 - Abstract #WSMRF2022WSMRF_466;
Tecarfarin has most of the benefits associated with warfarin but with less drug-drug interaction and a decrease kidney dependent metabolism...Conclusions Our review suggests there are multiple novel anticoagulants that may diversify the current EHRA and AHA recommendations for patients with concomitant Afib and ESRD. Although these therapies have demonstrated non-inferiority to warfarin, higher level trials are needed to further establish their therapeutic index and efficacy in the context of Afib and ESRD.
- |||||||||| tecarfarin (ATI-5923) / Espero BioPharma
Enrollment closed, Trial completion date, Trial primary completion date: A Study to Evaluate the Safety and Tolerability of Tecarfarin in Healthy Chinese Volunteers (clinicaltrials.gov) - Sep 23, 2019
P1, N=40, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Oct 2019 | Trial primary completion date: Nov 2018 --> Jul 2019
- |||||||||| tecarfarin (ATI-5923) / Espero BioPharma
Enrollment change, Trial initiation date, Trial primary completion date, Real-world evidence, Real-world: Tecarfarin Anti-Coagulation Trial (TACT) (clinicaltrials.gov) - Jan 25, 2018
P3, N=1000, Not yet recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Oct 2019 | Trial primary completion date: Nov 2018 --> Jul 2019 N=3000 --> 1000 | Initiation date: Dec 2016 --> Jun 2018 | Trial primary completion date: Mar 2018 --> Mar 2019
- |||||||||| tecarfarin (ATI-5923) / Espero BioPharma
Trial initiation date, Real-world evidence, Real-world: Tecarfarin Anti-Coagulation Trial (TACT) (clinicaltrials.gov) - Jun 24, 2016
P3, N=3000, Not yet recruiting,
N=3000 --> 1000 | Initiation date: Dec 2016 --> Jun 2018 | Trial primary completion date: Mar 2018 --> Mar 2019 Initiation date: Nov 2015 --> Dec 2016
- |||||||||| tecarfarin (ATI-5923) / Espero BioPharma
New P3 trial, Real-world evidence, Real-world: Tecarfarin Anti-Coagulation Trial (TACT) (clinicaltrials.gov) - Aug 13, 2015
P3, N=3000, Not yet recruiting,
|
